Dr David Stamler
Chief Medical Officer and Senior Vice President, Clinical De
Prana Biotechnology
Australia
Biography
David Stamler, M.D., is the Chief Medical Officer and Senior Vice President, Clinical Development at Prana Biotechnology, based in San Francisco. Prior to joining Prana, Dr. Stamler worked for Teva Pharmaceuticals, as part of Teva’s US$3.5 billion acquisition of Auspex Pharmaceuticals. Dr. Stamler led the development of a new drug for the treatment of Huntington’s disease, which was approved by the U.S. Food and Drug Administration (FDA) in April this year. This was the second neurological agent that Dr. Stamler has led through the approval process with the FDA.
Research Interest
Clinical Development
